REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $31.63.

Several research analysts have weighed in on the stock. Raymond James started coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. Morgan Stanley lifted their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. The Goldman Sachs Group decreased their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday. HC Wainwright dropped their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st.

Institutional Trading of REGENXBIO

Large investors have recently made changes to their positions in the company. FMR LLC increased its stake in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares during the period. BNP Paribas Financial Markets increased its stake in shares of REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after acquiring an additional 17,533 shares during the period. Stifel Financial Corp increased its stake in shares of REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after acquiring an additional 17,563 shares during the period. Barclays PLC raised its holdings in REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock valued at $11,422,000 after purchasing an additional 44,037 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Trading Down 3.6 %

NASDAQ RGNX traded down $0.22 on Wednesday, reaching $5.94. 649,002 shares of the company were exchanged, compared to its average volume of 800,635. REGENXBIO has a fifty-two week low of $5.04 and a fifty-two week high of $17.52. The stock has a market capitalization of $297.69 million, a P/E ratio of -1.18 and a beta of 1.26. The business's fifty day moving average price is $6.84 and its 200 day moving average price is $8.18.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. Equities research analysts forecast that REGENXBIO will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.